

DAFTAR PUSTAKA

- Afsar, B., Afsar, R. E., Caliskan, Y. & Lentine, K. L. (2024). The relationship between sclerostin and kidney transplantation mineral bone disorders: a molecule of controversies. *Calcified Tissue International*. <https://doi.org/10.1007/s00223-024-01261>
- Alam, M., Kirton, J. P., Wilkinson, F., Towers, E., Sinha, S., Rouhi, M., et al. (2009). Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. *Cardiovascular Research*, 81, 260–268.
- Andress, D. L. (2008). Adynamic bone in patients with chronic kidney disease. *Kidney International*, 73, 1345–1354.
- Barbuto, S., Hu, L., Abenavoli, C., Picotti, M., Manna, G. Ia, de Nicola, L., Genovesi, S. & Provenzano, M. (2024). Coronary artery disease in patients undergoing hemodialysis: a problem that sounds the alarm. *Reviews in Cardiovascular Medicine*, 25(6). <https://doi.org/10.31083/j.rcm2506200>
- Bellasi, A., Ferramosca, E., Muntner, P., Ratti, P., Wildman, R. P., Block, G. A., et al. (2006). Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. *Kidney International*, 70, 1623–1628.
- Block, G. A. & Port, F. K. (2003). Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. *Seminars in Dialysis*, 16(2), 140–147.
- Brandenburg, V. M., Kramann, R., Koos, R., Krüger, T., Schurgers, L., Mühlenbruch, G., Hübner, S., Gladziwa, U., Drechsler, C. & Ketteler, M. (2013). Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. *BMC Nephrology*, 14(219). <https://doi.org/10.1186/1471-2369-14-219>
- Brandenburg, V. M., Verhulst, A., Babler, A., D’Haese, P., Evenepoel, P. & Kaesler, N. (2019). Sclerostin in chronic kidney disease–mineral bone disorder: think first before you block it! *Nephrology Dialysis Transplantation*, 34(3), 408–414. <https://doi.org/10.1093/ndt/gfy129>
- Cao, Q., Shi, Y., Liu, X., Yang, F., Li, X. & Li, Z. (2024). Analysis of factors influencing vascular calcification in peritoneal dialysis patients and their impact on long-term prognosis. *BMC Nephrology*, 25(1). <https://doi.org/10.1186/s12882-024-03582-2>
- Catarina Marreiros, C., Viegas, C. & Simes, D. (2022). Targeting a silent disease: vascular calcification in chronic kidney disease. *International Journal of Molecular Sciences*, 23(24), 16114. <https://doi.org/10.3390/ijms232416114>

- Cejka, D., Herberth, J., Branscum, A. J., et al. (2014). Sclerostin and mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology*, 9(2), 224–233. <https://doi.org/10.2215/CJN.05410513>
- Chen, N. C., Hsu, C. Y. & Chen, C. L. (2017). The strategy to prevent and regress vascular calcification in dialysis patients. *BioMed Research International*, 2017, 9035193. <https://doi.org/10.1155/2017/9035193>
- Chen, N. X. & Moe, S. M. (2012). Pathophysiology of vascular calcification. *Current Osteoporosis Reports*, 10(4), 264–271.
- Cozzolino, M., Ciceri, P., Galassi, A., Mangano, M., Carugo, S., Capelli, I., et al. (2019). The key role of phosphate on vascular calcification. *Toxins*, 11, 213.
- Demirci, R. & Sevinc, C. (2021). The relationship between serum sclerostin levels and carotid intima media thickness in predialysis chronic kidney disease. *Egyptian Journal of Hospital Medicine*, 84.
- Drechsler, C., Evenepoel, P., Ketteler, M., et al. (2015). High levels of circulating sclerostin are associated with better cardiovascular survival in dialysis patients. *Kidney International*, 87(3), 693–701.
- Dreyer, T. J., Keen, J. A., Wells, L. M. & Roberts, S. J. (2023). Novel insights on the effect of sclerostin on bone and other organs. *Journal of Endocrinology*, 257(2), 83–101. <https://doi.org/10.1530/JOE-22-0209>
- Elarbagy, A. R., Yassein, Y. S., Emara, M. M., Sonbol, A. A., Elzorkany, K. M. A. & el Deen, A. A. S. (2019). Study of serum sclerostin levels and its role in vascular calcification in patients with chronic kidney disease. *Egyptian Journal of Internal Medicine*, 31(4), 813–821. https://doi.org/10.4103/ejim.ejim_34_19
- El Baz, T. Z., Saad, A. A. E. D. A., Emam, E. M. A., Mohammed, N. E.-G. & Omar, E. Y. A. (2023). Assessment of serum sclerostin level and its relationship to coronary calcifications in chronic kidney disease patients. *Al-Azhar International Medical Journal*, 4(1).
- Evenepoel, P., Brandenburg, V. M., Floege, J., et al. (2015). Sclerostin in chronic kidney disease: new perspectives. *Kidney International*, 87(4), 692–704.
- Evenepoel, P., D'Haese, P. C. & Brandenburg, V. M. (2019). Sclerostin and bone–vascular axis in CKD: is there a link? *Nephrology Dialysis Transplantation*, 34(4), 553–562.
- Figurek, A., Rroji, M. & Spasovski, G. (2020). Sclerostin: a new biomarker of CKD–MBD. *International Urology and Nephrology*, 52(1), 107–113.
- Fayed, A., Abdulazim, D. O., Amin, M., Elhadidy, S., Samir, H. H., Salem, M. M., Abd ElAzim, I. M., el Hawary, K. E. S. & Sharaf El Din, U. A. (2022). Serum

- sclerostin in acute kidney injury patients. *Nefrologia*, 42(1), 50–55.
<https://doi.org/10.1016/j.nefro.2021.01.010>
- Frederico, G. B., Voute, M. T., Hoeks, S. E., Chonchol, M. B., Boersma, E. E., Stolker, R. J., et al. (2012). Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. *Heart*, 98, 988–994.
- Golledge, J. & Thanigaimani, S. (2022). Role of sclerostin in cardiovascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 42(7), e187–e202. <https://doi.org/10.1161/ATVBAHA.122.317635>
- Honkanen, E., Kauppila, L. I., Wikström, B., et al. (2008). Abdominal aortic calcification in dialysis patients: validation of Kauppila score against CT. *Nephrology Dialysis Transplantation*, 23(5), 1639–1644.
- Hutcheson, J. D. & Goettsch, C. (2023). Cardiovascular calcification heterogeneity in chronic kidney disease. *Circulation Research*, 132(8), 993–1012. <https://doi.org/10.1161/CIRCRESAHA.123.321760>
- Inagaki, K., Tawada, N., Takanashi, M. & Akahori, T. (2022). The association between body mass index and all-cause mortality in Japanese patients with incident hemodialysis. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0269849>
- Jean, G., Chazot, C., Bresson, E., Zaoui, E. & Cavalier, E. (2016). High serum sclerostin levels are associated with a better outcome in haemodialysis patients. *Nephron*, 132(3), 181–190. <https://doi.org/10.1159/000443845>
- Jin, S., Zhu, M., Yan, J., Fang, Y., Lu, R., Zhang, W., Zhang, Q., Lu, J., Qi, C., Shao, X., Zhang, H., Jiang, R. & Ni, Z. (2016). Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. *Biomarkers in Medicine*, 10(7), 689–699. <https://doi.org/10.2217/bmm-2016-0031>
- Jialin, W., Yi, Z. & Weijie, Y. (2012). Relationship between body mass index and mortality in hemodialysis patients: a meta-analysis. *Nephron Clinical Practice*, 121, c102–c111.
- Jono, S., McKee, M. D., Murray, C. E., et al. (2000). Phosphate regulation of vascular smooth muscle cell calcification. *Circulation Research*, 87, e10–e17.
- Kanbay, M., Solak, Y., Siriopol, D., Aslan, G., Afsar, B., Yazici, D. & Covic, A. (2016). Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. *International Urology and Nephrology*, 48(12), 2029–2042.
- Kauppila, L. I., Polak, J. F., Cupples, L. A., Hannan, M. T., Kiel, D. P. & Wilson, P. W. (1997). New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. *Atherosclerosis*, 132, 245–250.

- KDIGO (2017). KDIGO 2017 Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). *Kidney International Supplements*, 7, 1–59.
- Kuo, T. H., Lin, W. H., Chao, J. Y., Wu, A. B., Tseng, C. C., Chang, Y. T., Liou, H. H. & Wang, M. C. (2019). Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study. *BMC Nephrology*, 20(1). <https://doi.org/10.1186/s12882-019-1452-5>
- Lin, Y., Mao, L., Chen, S. & Zhou, C. (2023). Serum sclerostin in vascular calcification in CKD: a meta-analysis. *Renal Failure*, 45(1). <https://doi.org/10.1080/0886022X.2023.2186151>
- Moe, S. M. & Chen, N. X. (2008). Mechanisms of vascular calcification in chronic kidney disease. *Journal of the American Society of Nephrology*, 19(2), 213–216.
- Morena, M., Jaussent, I., Dupuy, A. M., Bargnoux, A. S., Kuster, N., Chenine, L., Leray-Moragues, H., Klouche, K., Vernhet, H., Canaud, B. & Cristol, J. P. (2015). Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. *Nephrology Dialysis Transplantation*, 30(8), 1345–1356.
- Oliveira, F., Bonato, B., Karohl, C., Eugenia, M. & Canziani, F. (2021). Diagnosis of vascular calcification related to mineral and bone metabolism disorders in chronic kidney disease. *Jornal Brasileiro de Nefrologia*, 43(4 Suppl. 1), 628–631.
- Pateinakis, P. & Papagianni, A. (2013). Fibroblast growth factor-23 and adverse clinical outcomes in chronic kidney disease patients. *OA Nephrology*, 1(1), 4.
- Paolis, P. de, Colonnelli, R., Favaro, A., Iappelli, M., Carriero, C., Mantella, D., Coen, G. & Giulio, S. di (2013). Modifications of coronary artery calcifications (CAC) and correlations with C reactive protein (CRP) levels in renal recipients after the first year of transplantation. *Open Journal of Nephrology*, 3(1), 1–5. <https://doi.org/10.4236/ojneph.2013.31001>
- Pereira, L., Mendonça, L., Magalhães, J., Neto, R., Quelhas-Santos, J., Oliveira, A., Beco, A. & Frazão, J. (2024). Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone histomorphometry. *Nefrologia*, 44(2), 224–232. <https://doi.org/10.1016/j.nefro.2023.01.005>
- Perhimpunan Nefrologi Indonesia (PERNEFRI) (2003). *Konsensus Dialisis*. Jakarta: Perhimpunan Nefrologi Indonesia.
- Ren, S. C., Mao, N., Yi, S., Ma, X., Zou, J. Q., Tang, X. & Fan, J. M. (2022). Vascular calcification in chronic kidney disease: an update and perspective. *Aging and Disease*, 13(3), 673–697. <https://doi.org/10.14336/AD.2021.1024>

- Roumeliotis, S., Roumeliotis, A., Dounousi, E., Eleftheriadis, T. & Liakopoulos, V. (2020). Biomarkers of vascular calcification in serum. *Advances in Clinical Chemistry*, 98, 91–147. <https://doi.org/10.1016/bs.acc.2020.02.004>
- Salam, S., Gallagher, O., Gossiel, F., Paggiosi, M., Eastell, R. & Khwaja, A. (2021). Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. *Bone*, 143. <https://doi.org/10.1016/j.bone.2020.115699>
- Shanahan, C. M., Crouthamel, M. H., Kapustin, A. & Giachelli, C. M. (2011). Arterial calcification in CKD: key roles for calcium and phosphate. *Circulation Research*, 109, 697–711.
- Siracusa, C., Carabetta, N., Morano, M. B., Manica, M., Strangio, A., Sabatino, J., Leo, I., Castagna, A., Cianflone, E., Torella, D., Andreucci, M., Zicarelli, M. T., Musolino, M., Bolignano, D., Coppolino, G. & de Rosa, S. (2024). Understanding vascular calcification in chronic kidney disease: pathogenesis and therapeutic implications. *International Journal of Molecular Sciences*, 25(23). <https://doi.org/10.3390/ijms252313096>
- Smeltzer, S. C. & Bare, B. G. (2013). Textbook reference for CAPD procedures. (Jika diperlukan, lengkapi dengan edisi dan penerbit.)
- Srisuwarn, P., Eastell, R. & Salam, S. (2024). Clinical utility of bone turnover markers in chronic kidney disease. *Journal of Bone Metabolism*, 31(4), 264–278. <https://doi.org/10.11005/jbm.24.789>
- Suwitra, K., Lydia, A., Susalit, E., Suhardjono, Yogiartoro, Prodjosudjadi, W., et al. (2009). Konsensus gangguan mineral dan tulang pada penyakit ginjal kronik (GMT-PGK). PERNEFRI. Jakarta: Perhimpunan Nefrologi Indonesia.
- Tsukada, M., Miwa, N., Hanafusa, N., Tanaka, N., Tsuchiya, K. & Nitta, K. (2019). Aortic arch calcification and bone-associated molecules in peritoneal dialysis patients. *Blood Purification*, 47(Suppl2), 81–87. <https://doi.org/10.1159/000496657>
- Viera, A. & Garret, J. (2005). Understanding interobserver agreement: the Kappa statistic. *Family Medicine*, 37(5), 360–363.
- Wang, X. R., Yuan, L., Zhang, J. J., Hao, L. & Wang, D. G. (2017). Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. *Nephrology*, 22(4), 286–292. <https://doi.org/10.1111/nep.12813>
- Waziri, B., Duarte, R. & Naicker, S. (2019). Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives. *International Journal of Nephrology and Renovascular Disease*, 12, 263–276.
- Wu, C. F., Hou, J. S., Wang, C. H., Lin, Y. L., Lai, Y. H., Kuo, C. H., Liou, H. H., Tsai, J. P. & Hsu, B. G. (2020). Serum sclerostin but not DKK-1 correlated with central arterial stiffness in end stage renal disease patients. *International*

Journal of Environmental Research and Public Health, 17(4).
<https://doi.org/10.3390/ijerph17041290>

Yamada, S., et al. (2016). Higher circulating sclerostin levels in peritoneal dialysis than hemodialysis: clinical implications. *Kidney Research and Clinical Practice*, 35(4), 277–286.

Zadeh, K., Abbot, K., Salahudeen, A., Kilpatrick, R. & Horwich, T. (2005). Survival advantages of obesity in dialysis patients. *American Journal of Clinical Nutrition*, 81, 543–554.

Zhao, Y., Wang, W. & Dong, Z. (2020). What is the relationship between sclerostin and cardiovascular events in hemodialysis patients? *Renal Failure*, 42(1), 1164–1165. <https://doi.org/10.1080/0886022X.2020.1845733>

Zeng, C., Guo, C., Cai, J., Tang, C. & Dong, Z. (2018). Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. *Diabetes and Vascular Disease Research*, 15(2), 99–105.
<https://doi.org/10.1177/1479164117742318>